Steinar Aamdal

  • 5785 Citations
  • 39 h-Index
1984 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Steinar Aamdal is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Dacarbazine Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Vaccination Medicine & Life Sciences
apaziquone Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1984 2019

  • 5785 Citations
  • 39 h-Index
  • 105 Article
  • 3 Letter
  • 2 Comment/debate
  • 2 Review article

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M. & Ueland, T., Jul 1 2019, In : Clinical and Experimental Immunology. 197, 1, p. 74-82 9 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Endostatins
Galectin 3
Biomarkers
11 Citations (Scopus)

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

Schöffski, P., Wozniak, A., Kasper, B., Aamdal, S., Leahy, M. G., Rutkowski, P., Bauer, S., Gelderblom, H., Italiano, A., Lindner, L. H., Hennig, I., Strauss, S., Zakotnik, B., Anthoney, A., Albiges, L., Blay, J. Y., Reichardt, P., Sufliarsky, J., van der Graaf, W. T. A., Debiec-Rychter, M. & 6 others, Sciot, R., Van Cann, T., Marréaud, S., Raveloarivahy, T., Collette, S. & Stacchiotti, S., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 758-765 8 p.

Research output: Contribution to journalArticle

Alveolar Soft Part Sarcoma
Transcription Factors
Organizations
Safety
Research
6 Citations (Scopus)

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’

Schöffski, P., Wozniak, A., Leahy, M. G., Aamdal, S., Rutkowski, P., Bauer, S., Richter, S., Grünwald, V., Debiec-Rychter, M., Sciot, R., Geoerger, B., Marréaud, S., Collette, S., Nzokirantevye, A. & Strauss, S. J., May 1 2018, In : European Journal of Cancer. 94, p. 156-167 12 p.

Research output: Contribution to journalArticle

Alveolar Rhabdomyosarcoma
Protein-Tyrosine Kinases
Confidence Intervals
Disease-Free Survival
anaplastic lymphoma kinase
10 Citations (Scopus)

Acute liver graft rejection after ipilimumab therapy

Dueland, S., Guren, T. K., Boberg, K. M., Reims, H. M., Grzyb, K., Aamdal, S., Julsrud, L. & Line, P. D., Jan 1 2017, In : Annals of Oncology. 28, 10, p. 2619-2620 2 p.

Research output: Contribution to journalLetter

Graft Rejection
Liver
Therapeutics
ipilimumab
9 Citations (Scopus)

Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine

Sioud, M., Nyakas, M., Sæbøe-Larssen, S., Mobergslien, A., Aamdal, S. & Kvalheim, G., Jan 1 2016, In : Case Reports in Medicine. 2016, 9639585.

Research output: Contribution to journalArticle

Indoleamine-Pyrrole 2,3,-Dioxygenase
Dendritic Cells
Immunity
Melanoma
Neoplasm Antigens